Advertisement

Topics

Heron initiates phase 3 program for HTX-011 in postoperative pain

05:56 EDT 10 Aug 2017 | Pharmaceutical Business Review

Heron Therapeutics has reported positive outcome of a recent End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) regarding its investigational agent, HTX-011, to prevent postoperative pain for the first 72 hours post surgery.

Original Article: Heron initiates phase 3 program for HTX-011 in postoperative pain

NEXT ARTICLE

More From BioPortfolio on "Heron initiates phase 3 program for HTX-011 in postoperative pain"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pain
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...